-
Tumor mutational burden (TMB) has emerged as a significant biomarker in cancer research and treatment. TMB refers to the total number of mutations present in a tumor's DNA and can vary across different types of cancer. A high tumor mutational burden often correlates with a better response to immune checkpoint inhibitors, making it an essential factor in personalized cancer therapy. Researchers and clinicians are increasingly using TMB to predict patient responses to immunotherapy, as tumors with a higher mutational burden tend to have more neoantigens, which can be recognized by the immune system. As a result, tumor mutational burden is becoming a crucial tool for guiding treatment decisions in oncology.
-
Category
Research -
Created
Friday, 14 February 2025 -
Group admin
Gemini Smith
My Portfolio
Close X
Mentor Center
